SYSTEMATIC REVIEW article

Front. Pharmacol., 21 January 2022

Sec. Pharmacoepidemiology

Volume 12 - 2021 | https://doi.org/10.3389/fphar.2021.802097

Does Having a Usual Primary Care Provider Reduce Polypharmacy Behaviors of Patients With Chronic Disease? A Retrospective Study in Hubei Province, China

  • 1. School of Pharmacy, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China

  • 2. School of Medicine and Health Management, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China

  • 3. Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

  • 4. Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Article metrics

View details

13

Citations

4,1k

Views

1,6k

Downloads

Abstract

Background: Within China's hierarchical medical system, many patients seek medical care in different hospitals independently without integrated management. As a result, multi-hospital visiting is associated with fragmented service utilization and increased incidence of polypharmacy behaviors, especially for patients with chronic disease. It has been confirmed that factors from the perspective of patients may cause polypharmacy behaviors in Chinese community patients; whether having a usual primary care provider for chronic disease patients could reduce the polypharmacy behaviors and the effect size remains unanswered, and that is what our study aimed to answer.

Methods: Our study adopted a cluster sampling method to select 1,196 patients with hypertension or diabetes and measured some information about them. The propensity score weighting method was adopted to eliminate the influence of confounding bias, and then a multivariate logistic regression model was conducted to test the relationship between having a usual primary care provider and polypharmacy behaviors.

Results: Patients without usual primary care providers were significantly correlated with polypharmacy behaviors (OR = 2.40, 95%CI: 1.74–3.32, p < 0.001), and the corresponding marginal effect is 0.09 (95%CI: 0.06–0.12). Patients who suffer from two kinds of diseases (OR = 3.05, 95%CI: 1.87–5.10, p < 0.001), with more than three kinds of diseases (OR = 21.03, 95%CI: 12.83–35.65, p < 0.001), with disease history of 20 years and above (OR = 1.66, 95%CI: 1.14–2.42, p = 0.008), who communicate frequently with doctors (OR = 3.14, 95%CI: 1.62–6.19, p < 0.001), alcoholic patients (OR = 2.14, 95%CI: 1.08–4.19, p = 0.027), who used to have meat-based food (OR = 1.42, 95%CI: 1.00–2.00, p = 0.049), and have vegetarian-based diet (OR = 1.42, 95%CI: 1.00–2.00, p = 0.049) are more likely to have polypharmacy behaviors, while patients aged between 65 and 75 years (OR = 0.50, 95%CI: 0.33–0.77, p = 0.020), used to be brain workers (OR = 0.67, 95%CI: 0.45–0.99, p = 0.048), with disease history between 10 and 20 years (OR = 0.56, 95%CI: 0.37–0.83, p = 0.005), have had adverse drug reactions (OR = 0.64, 95%CI: 0.45–0.93, p = 0.019), and participated in medical insurance for urban and rural residents (OR = 0.35, 95%CI: 0.21–0.58, p < 0.001) were less likely to have polypharmacy behaviors.

Conclusion: The results suggest that having a usual primary care provider may reduce the incidence of having polypharmacy behaviors; we can take intervention measures to promote establishing a long-term relationship between patients and primary care providers.

Systematic Review Registration: [website], identifier [registration number]

Introduction

Chronic non-communicable diseases (NCDs) are a kind of disease with insidious onset, long incubation period, long and slow course, uncured, lack of convinced evidence of biological etiology, and no clear indications for treatment. As the population ages, NCDs have become one of the greatest threats to public health. According to the World Health Statistics Report 2021 released by the WHO, 7 of the top 10 causes of death in 2019 were chronic diseases. In 2000, 60.8% of patients died from NCDs, and the proportion rose to 73.6% in 2019. Demographic changes such as the aging of the population promote the development of multimorbidity of chronic conditions (Xu et al., 2017). Multimorbidity always leads to polypharmacy behaviors among patients with chronic diseases. Polypharmacy behaviors have been considered to be an increasingly serious public health problem worldwide, especially among the elderly (Payne and Avery, 2011; Wastesson et al., 2018). The vast majority of studies defined taking five or more drugs at the same time as polypharmacy behaviors (Kaufman et al., 2002; Fialová, 2005; Payne and Avery, 2011; Mortazavi et al., 2016; Masnoon et al., 2017; Wastesson et al., 2018). A study in United States showed that 29.0% of elderly people used at least five prescription drugs. Another survey on community residents showed that 37.1% of men aged 75 to 85 years and 36.0% of women took five or more prescription drugs at the same time (Hoel et al., 2021). In the 2016 UK Health Survey, 56.0% of people aged ≥85 years took five or more drugs (UK.GOV, 2021), while about 9.0% of people aged 45–54 years took the same. A review report of polypharmacy behaviors found that the incidence of polypharmacy behaviors in various countries ranged from 38.1% to 91.2% (Jokanovic et al., 2015). Polypharmacy behaviors are becoming increasingly popular.

It has been reported that patients who take five medications have at least one serious medication problem (Strand et al., 1990; Hanlon et al., 2006). Polypharmacy behaviors are associated with an increase in adverse drug reactions, lower compliance, inappropriate drug therapies, and higher medical expenditure (Field et al., 2001; Goulding, 2004; Lau et al., 2005; Payne and Avery, 2011; Wastesson et al., 2018). Some other studies have also found that polypharmacy behaviors are associated with rehospitalization, falls, death, and poor health outcomes (Bushardt et al., 2008; Cooney and Pascuzzi, 2009; Dhalwani et al., 2017; Leelakanok et al., 2017). It also increases the economic burden of the health system (Fulton and Riley Allen, 2005).

The occurrence of polypharmacy behaviors is related to many factors. From the patients' perspective, demographic factors such as age, education, health behaviors (smoking, drinking, exercise, and daily eating habits) have significantly related to polypharmacy behaviors. In addition, disease-related factors have also been confirmed to cause polypharmacy behaviors in patients with chronic diseases. Many studies have found that the type of disease, the number of diseases, and the severity of the disease will affect the occurrence of polypharmacy behaviors in patients with chronic diseases (Bronskill et al., 2012; Liu et al., 2021). Medical cause has also been confirmed to be related to patients' polypharmacy behaviors. Inpatients had an average of two more drugs when compared with outpatients (Betteridge et al., 2012; Viktil et al., 2012). The disorder of multi-institution medical treatment and the lack of comprehensive management of patients' multi-institution medical treatment leads to problems such as repeated prescription, excessive prescription, misuse of prescription, and prescribing cascade, thus leading to polypharmacy behaviors (O'Connor et al., 2012). Moreover, from the care provider perspective, patients were consulted in different medical institutions and departments, resulting in doctor–patient communication not being smooth, fragmentation of medication regimen, and increased risk of polypharmacy behaviors. Some patients prefer to seek healthcare in different hospitals, which could not provide integrated medication recommendations and always resulted in repeat or unnecessary medication. However, few studies measured the factors that influenced polypharmacy behaviors in terms of service utilization and usual primary health care in China; whether having a usual primary care provider for chronic disease patients could reduce the polypharmacy behaviors and the effect size remains unanswered. On the whole, there is a research gap in exploring the relationship between usual care provider and polypharmacy behaviors. Our study aimed to explore the relationship between the usual primary health care and polypharmacy behaviors of patients with chronic diseases and quantify the impact effect.

Methods

Study Settings and Sampling

The data were collected by a cluster sampling method from April to June 2021, in which we first selected four cities (Zhijiang, Qianjiang, Yichang, and Wuhan) from Hubei province, China. Wuhan and Yichang were taken as urban sample areas, while Zhijiang and Qianjiang were taken as rural sample areas. Three streets or towns were randomly selected from each city (a total of 12), and every street or town needed to collect 100 patients diagnosed with hypertension or diabetes, which can be managed by primary health care providers. Exclusion criteria included those who had not been taking medicine for more than 3 months, those who were younger than 18 years, those who cannot express themselves clearly, those who were unwilling to cooperate with this investigation, those who were severely ill and cannot complete the questionnaire, and those diagnosed with acute complications. In total, 1,205 participants joined the survey; 9 of them were excluded due to lack of information.

Variables and Measurement

The primary predictor of interest in this study was whether a patient reported having a usual primary care provider. In this study, the usual primary care providers were determined by asking the patients “Which of the following institutions have you frequently visited in the past 3 months?” Respondents who frequently visited primary health care institutions were considered to have primary health care providers, and the others were considered to have no primary health care providers.

The dependent variable was whether patients had polypharmacy behaviors; they were considered to have polypharmacy behaviors if they took five or more drugs per day, and other patients were regarded as non-polypharmacy.

Confounding variables included demographic characteristics, clinical conditions, medical treatment behavior data, health information data of patients with chronic diseases, and medication knowledge of patients.

Demographic data included the patient's domicile, gender, age, education level, annual income, job type, and residence status. Job type is classified into brain workers and manual workers. Residence status is divided into live alone and not live alone.

Clinical conditions included the number of chronic diseases, disease history, adverse drug reactions (ADRs), and severity of disease. Disease history is calculated based on the question “when were you diagnosed with chronic disease?”

Patients' medical treatment behaviors data included whether in hospital in the past year, type of medical insurance, the frequency of communication with doctors, etc. The type of medical insurance was divided into employee health insurance and urban and rural resident medical insurance. The frequency of communication with doctors is classified as none, rarely, occasionally, often, and always.

Health information data included smoking status, drink status, physical activity, and whether people with chronic diseases had their blood pressure or blood sugar checked regularly.

Patient knowledge was evaluated through administration of a questionnaire adapted from the study by McPherson et al. (Mcpherson et al., 2008; Okuyan et al., 2013); the median was taken as the critical value to divide the total score of medication knowledge into high and low score groups of medication knowledge.

Statistical Analysis

A descriptive analysis of sample characteristics was performed on SPSS 24.0, and the other statistical analyses were performed on R Commander Version 4.04, which is a graphical user interface for R software. Multivariate logistic regression analysis was conducted to model the association between having a usual primary care provider and participants' polypharmacy behaviors. Propensity-score weighting approach was applied to adjust for the observed difference in characteristics between those having a usual primary care provider and those not having and therefore could better tease out the net influence of having a usual primary care provider on patients' polypharmacy behaviors. Odds ratios (ORs), marginal effects, and their 95% confidence intervals were reported to indicate the relationship between the two variables. Statistical significance was defined as a two-tailed p-value <0.05 in all analyses.

Ethics Statement

The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients. This study was approved by the Medical Ethics Committee of Tongji Medical College of Huazhong University of Science and Technology, and the approval number is 2020 (S223).

Results

Interviewee Information

As shown in Table 1, the characteristics of a total of 1,205 patients with chronic diseases who participated were collected in this survey, of which 1,196 completed questionnaires. About 71.0% (849/1,196) were 65 years old and above; the youngest patient was 26 years old, the oldest patient was 92 years old, and the average age was 68.55 years old. About 58.0% (693/1,196) were female. Approximately 48.3% (578/1,196) were living in the urban area. About 62.6% (749/1,196) were manual workers; 10.4% lived alone. In general, there were two kinds of chronic diseases per capita and three kinds of medication per capita taken. Two hundred fifty-two patients (21.1%) had polypharmacy behaviors. Adverse reactions occurred in 242 patients (20.2%), and 399 (33.7%) patients frequently visited primary medical institutions.

TABLE 1

Non-polypharmacy N (%)Polypharmacy N (%)Χ2p
A usual primary care provider
Yes352 (37.3)47 (18.7)31.077<0.001
No592 (62.7)205 (81.3)
Gender
 Male397 (42.1)106 (42.1)0.0000.998
 Female547 (57.9)146 (57.9)
Age (years)
 18–65280 (29.7)67 (26.6)5.2490.072
 66–75508 (53.8)124 (49.2)
 >75156 (16.5)61 (24.2)
Domicile
 Urban area436 (46.2)142 (56.3)8.2260.004
 Rural area508 (53.8)110 (43.7)
Education
 Primary school437 (46.3)106 (41.9)5.7230.126
 Middle school285 (30.2)76 (30.0)
 High school174 (18.5)49 (19.4)
 University47 (5.0)22 (8.7)
Job
 Manual worker611 (64.7)138 (54.8)8.4350.004
 Brain worker333 (35.3)114 (45.2)
Residence status
 Live alone93 (9.9)31 (12.3)1.2850.257
 Not live alone851 (90.1)221 (87.7)
Annual income per year
 0–9,999276 (29.2)67 (26.6)0.6830.711
 10,000–50,000310 (32.8)86 (34.1)
 >50,000358 (37.9)99 (39.3)
Number of diseases
 1445 (47.1)24 (9.5)134.1760.000
 2494 (52.3)216 (85.7)
 ≥35 (0.5)12 (4.8)
Disease history/year
 0–10497 (52.6)104 (41.3)14.2490.001
 11–20254 (26.9)71 (28.2)
 >20193 (20.4)77 (30.6)
Adverse disease reaction
 No783 (82.9)171 (67.9)28.054<0.001
 Yes161 (17.1)81 (32.1)
Severity of disease
 Mild433 (45.9)48 (19.0)97.1580.000
 Moderate386 (40.9)111 (44.0)
 Severe125 (13.2)93 (36.9)
Medical insurance
 Employee health insurance367 (38.9)120 (47.6)6.2970.012
 Resident health insurance577 (61.1)132 (52.4)
Hospitalization
 Yes291 (30.8)141 (56.0)54.422<0.001
 No653 (69.2)111 (44.0)
Communication frequency
 No127 (13.5)22 (8.7)22.421<0.001
 Rare291 (30.8)64 (25.4)
 Occasionally180 (19.1)50 (19.8)
 Often276 (29.2)75 (29.8)
 Always70 (7.4)41 (16.3)
Drink
 Never733 (77.6)214 (84.9)7.9450.047
 Occasionally115 (12.2)16 (6.3)
 Often29 (3.1)7 (2.8)
 Always67 (7.1)15 (6.0)
Smoking
 Never685 (72.6)195 (77.4)7.4590.024
 Have quit smoking105 (11.1)33 (13.1)
 Smoking154 (16.3)24 (9.5)
Diet
 Balance522 (55.3)115 (45.6)7.9250.019
 Mainly meat65 (6.9)18 (7.1)
 Mainly vegetarian357 (37.8)119 (47.2)
Exercise
 Never109 (11.5)43 (17.1)8.4020.038
 Occasionally166 (17.6)52 (20.6)
 Often193 (20.4)50 (19.8)
 Always476 (50.4)107 (42.5)
Blood pressure measurement
 Irregular178 (18.9)33 (13.1)4.5430.033
 Regular766 (81.1)219 (86.9)
Knowledge of medication
 Low482 (51.1)125 (49.6)0.1690.681
 High462 (48.9)127 (50.4)

Characteristics of the study population.

Propensity Score Weighted Results

Standardized mean difference is an indicator used to evaluate the balance between the experimental group and the control group before and after weighting, using a threshold of 0.10 to indicate imbalance. As shown in Table 2, after propensity score weighting, covariates with large deviations in the original data are balanced, and the overall distribution of the data is more balanced.

TABLE 2

VariableStandardized mean difference
Before weightAfter weight
Gender−0.090.09
Age0.270.00
Domicile−1.070.06
Education0.530.00
Job0.580.04
Residence status0.000.11
Annual income0.630.06
Number of diseases0.290.00
Disease history0.290.05
Adverse disease reaction−0.16−0.09
Severity of disease0.49−0.11
Medical insurance−0.90−0.07
Hospitalization−0.180.11
Communication frequency−0.3−0.05
Drink−0.08−0.05
Smoking−0.03−0.07
Diet−0.26−0.06
Exercise−0.04−0.05
Regular blood pressure measurement−0.10−0.07
Knowledge of medication0.18−0.03

The standardized mean difference of each covariable before and after weighting.

Regression Analysis Results

Tables 3, 4 present the results from multivariate logistic regressions and propensity scores weighting regressions. In this model, we calculated both ORs and marginal effects of each variable. The results of the weighted regression are different from the results of the multivariate logistic regression. The multivariate logistic regression underestimates the impact of having a usual primary care provider on the patient's multiple medication behaviors due to crowd confounding factors. Result from the propensity scores weighted regression showed that having no usual primary care providers was significantly associated with the odds of polypharmacy behaviors (OR = 2.40, 95%CI: 1.74–3.32, p < 0.001), and the corresponding marginal effect was 0.09 (95% CI: 0.06–0.12), indicating that patients having a usual primary care provider are less likely to have polypharmacy behaviors.

TABLE 3

VariableBefore weightingAfter weighting
OR (95%CI)pOR (95%CI)p
A usual primary care provider
Yes
 No1.5 (0.98–2.31)0.0652.40 (1.74–3.32)<0.001
Gender
 Male
  Female0.76 (0.48–1.21)0.2481.32 (0.87–2.03)0.192
Age (years)
 18–65
  66–750.65 (0.42–1.01)0.0530.50 (0.33–0.77)0.002
  >750.97 (0.56–1.68)0.9141.03 (0.62–1.69)0.921
Domicile
 Urban area
  Rural area0.47 (0.25–0.89)0.021.21 (0.68–2.17)0.523
Education
 Primary school
  Middle school1.24 (0.79–1.97)0.3501.13 (0.72–1.76)0.593
  High school1.41 (0.78–2.55)0.2561.45 (0.84–2.50)0.184
  University2.48 (1.09–5.6)0.0301.70 (0.81–3.57)0.161
Job
 Manual worker
  Brain worker1 (0.66–1.53)0.9920.67 (0.45–0.99)0.048
Residence status
 Live alone
  Not live alone1.06 (0.61–1.86)0.8401.41 (0.85–2.37)0.191
Annual income
 0–9,999
  10,000–50,0001.14 (0.7–1.85)0.6021.06 (0.67–1.69)0.809
  >50,0001 (0.57–1.77)0.9911.28 (0.77–2.15)0.345
Number of diseases
 1
  23.35 (2.02–5.71)<0.0013.05 (1.87–5.10)<0.001
  ≥314.01 (8.34–24.39)<0.00121.03 (12.83–35.65)<0.001
Disease history/year
 0–10
  11–200.85 (0.56–1.28)0.4350.56 (0.37–0.83)0.005
  >201.12 (0.73–1.72)0.6031.66 (1.14–2.42)0.008
Adverse disease reaction
 No
  Yes0.81 (0.54–1.21)0.2940.64 (0.45–0.93)0.019
Severity of disease
 Mild
  Moderate1.47 (0.96–2.25)0.0791.36 (0.90–2.09)0.150
  Severe2.3 (1.38–3.82)0.0011.63 (1.00–2.67)0.049
Medical insurance
 Employee health insurance
  Resident health insurance1.01 (0.55–1.82)0.9750.35 (0.21–0.58)<0.001
Hospitalization
 No
  Yes0.54 (0.38–0.77)<0.0010.83 (0.60–1.15)0.260
Communication frequency
 No
  Rare1.39 (0.76–2.64)0.2961.06 (0.62–1.85)0.838
  Occasionally1.41 (0.73–2.77)0.3131.14 (0.62–2.10)0.673
  Often1.44 (0.77–2.8)0.2651.19 ((0.68–2.14)0.561
  Always3.17 (1.51–6.82)0.0033.14 (1.62–6.19)<0.001
Drink
 Never
  Occasionally0.53 (0.26–1.02)0.0660.69 (0.36–1.28)0.254
  Often1.26 (0.42–3.45)0.6631.12 (0.38–3.00)0.828
  Always1.42 (0.66–2.94)0.3542.14 (1.08–4.19)0.027
Smoking
 Never
  Have quit smoking0.83 (0.45–1.51)0.5551.36 (0.81–2.28)0.245
  Smoking0.58 (0.3–1.06)0.0840.60 (0.32–1.10)0.105
Diet
 Balance
  Mainly meat1.78 (0.88–3.48)0.0982.01 (1.05–3.73)0.030
  Mainly vegetarian1.67 (1.16–2.41)0.0061.42 (1.00–2.00)0.049
Exercise
 Never
  Occasionally1.29 (0.72–2.32)0.3871.20 (0.70–2.05)0.504
  Often1.01 (0.56–1.82)0.9841.33 (0.78–2.27)0.296
  Always0.95 (0.56–1.61)0.8361.00 (0.63–1.61)0.993
Blood pressure measurement
 Regular
  Irregular0.91 (0.55–1.49)0.7240.96 (0.59–1.53)0.859
Knowledge of medication
 low
  high0.99 (0.68–1.44)0.9740.91 (0.63–1.29)0.581
  Intercept0.248 (0.01–0.2)<0.0010.03 (0.01–0.09)<0.001

ultivariate logistic regression before and after propensity score weighting.

TABLE 4

VariablepMarginal effect (95%CI)
A usual primary care provider
Yes
No<0.0010.09 (0.06–0.12)
Gender
 Male
  Female0.1920.03 (−0.00 to 0.08)
Age (years)
 18–65
  66–750.002−0.08 (−0.12 to 0.03)
  >750.9210.00 (−0.08 to 0.06)
Domicile
 Urban area
  Rural area0.5230.02 (−0.04 to 0.08)
Education
 Primary school
  Middle school0.5930.01 (−0.03 to 0.06)
  High school0.1840.04 (−0.02 to 0.10)
  University0.1610.06 (−0.03 to 0.15)
Job
 Manual worker
  Brain worker0.048−0.04 (−0.08 to 0.00)
Residence status
 Live alone
  Not live alone0.1910.04 (−0.02 to 0.09)
Annual income
 0–9,999
  10,000–50,0000.8090.01 (−0.04 to 0.06)
  >50,0000.3450.03 (−0.03 to 0.08)
Number of diseases
 1
  2<0.0010.09 (0.05–0.12)
  ≥3<0.0010.40 (0.34–0.45)
Disease history/year
 0–10
  11–200.005−0.06 (−0.10 to 0.02)
  >200.0080.06 (0.01–0.11)
Adverse disease reaction
 No
  Yes0.019−0.05 (−0.09 to 0.01)
Severity of disease
 Mild
  Moderate0.1500.03 (−0.01 to 0.08)
  Severe0.0490.05 (−0.03 to 0.11)
Medical insurance
 Employee health insurance
  Resident health insurance<0.001−0.12 (−0.17 to 0.06)
Hospitalization
 No
  Yes0.260−0.02 (−0.06 to 0.02)
Communication frequency
 No
  Rare0.8380.01 (−0.05 to 0.06)
  Occasionally0.6730.01 (−0.05 to 0.08)
  Often0.5610.02 (−0.04 to 0.08)
  Always<0.0010.14 (0.06–0.22)
Drink
 Never
  Occasionally0.254−0.04 (−0.10 to 0.02)
  Often0.8280.01 (−0.10 to 0.13)
  Always0.0270.09 (0.00–0.18)
Smoking
 Never
  Have quit smoking0.2450.04 (−0.03 to 0.10)
  Smoking0.105−0.05 (−0.11 to 0.08)
Diet
 Balance
  Mainly meat0.0300.08 (0.00–0.16)
  Mainly vegetarian0.0490.04 (0.00–0.08)
Exercise
 Never
  Occasionally0.5040.02 (−0.04 to 0.08)
  Often0.2960.03 (−0.00 to 0.09)
  Always0.9930.00 (−0.05 to 0.05)
Regular blood pressure measurement
 Regular
  Irregular0.8590.00 (−0.06 to 0.05)
Knowledge of medication
 low
  high0.5810.01 (−0.05 to 0.03)
  Intercept<0.001

The marginal effect of each variable after propensity score weighting.

With regard to the covariates, we found that patients who aged between 65 and 75 years (OR = 0.50, 95%CI: 0.33–0.77, p = 0.020), used to be brain workers (OR = 0.67, 95%CI: 0.45–0.99, p = 0.048), have been sick for 10–20 years (OR = 0.56, 95%CI: 0.37–0.83, p = 0.005), have had adverse drug reactions (OR = 0.64, 95%CI: 0.45–0.93, p = 0.019), and purchased resident health insurance (OR = 0.35, 95%CI: 0.21–0.58, p < 0.001) were less likely to have polypharmacy behaviors. But patients who have two kinds of diseases (OR = 3.05, 95%CI: 1.87–5.10, p < 0.001) and above (OR = 21.03, 95%CI: 12.83–35.65, p < 0.001), have been sick for 20 years and above (OR = 1.66, 95%CI: 1.14–2.42, p = 0.008), with serious diseases (OR = 1.63, 95%CI: 1.00–2.67, p = 0.049), communicated with doctor frequently (OR = 3.14, 95%CI: 1.62–6.19, p < 0.001), with alcoholism (OR = 2.14, 95%CI: 1.08–4.19, p = 0.027), have a meat-based diet (OR = 1.42, 95%CI: 1.00–2.00, p = 0.049), and have a vegetarian-based diet (OR = 1.42, 95%CI: 1.00–2.00, p = 0.049) were more likely to have polypharmacy behaviors.

Discussion

The Effect of Having a Usual Primary Care Provider on Polypharmacy Behaviors

This study provided evidence that patients who did not have a usual primary care provider were more likely to have polypharmacy behaviors than those who had a usual primary care provider (OR = 2.40, 95%CI: 1.74–3.32, p < 0.001), with a marginal effect of 0.09 (95%CI: 0.06–0.12), which means that at the average level of other conditions, the probability of polypharmacy behaviors increased by 9.0% when patients who had a usual primary care provider changed to not having a usual primary care provider. In China, medical staff in primary medical institutions have more time to communicate with patients compared to the medical staff in general hospitals. Patients had established a close relationship with primary medical institutions so that they were more willing to seek the guidance of doctors from primary medical institutions in their daily lives (Starfield et al., 2005; Kruk et al., 2010; Feng et al., 2016). In addition, doctors in primary medical institutions are more familiar with patients, which reduces the enthusiasm of patients to seek doctors in advanced medical institutions and reduces the probability of doctors' repeated prescriptions due to untimely sharing of patient's information by patients (Zhang et al., 2013; Duckett et al., 2016).

Although China has established a hierarchical medical system for a long time, many patients go directly to general hospitals instead of primary medical institutions, which may be related to the unbalanced allocation of medical resources (Zhou et al., 2021). At present, there are fewer specialized medical staff in primary medical institutions (Chen et al., 2021), a higher turnover rate of grassroots medical staff (Dale et al., 2015), lower education (Chen et al., 2021), poor medical equipment, and lack of conventional drugs, which makes patients have low trust in primary medical institutions and reluctant to go to primary medical institutions.

With a study showing that patients with primary care providers are likely to reduce patient self-referrals in rural China's rural multi-tiered medical system (Feng et al., 2017) and another study showing that general practitioners (GPs) can effectively reduce patient referral behavior, health maintenance organizations (HMOs) in the United States require patients to consult a primary care physician firstly before considering a referral (Sekhri, 2000; Hoel et al., 2021). Many European countries have GP systems that can effectively guide patients through graded care (Verhaak et al., 2004; Brown et al., 2014).

We need to give play to the role of primary medical institutions. On the one hand, we need to strengthen the construction of primary medical institutions and ensure the complete resources of personnel, equipment, drugs, and other resources in primary medical institutions, so as to restore the trust of patients in primary medical institutions (Liu et al., 1996; Yip and Hsiao, 2014; Shi et al., 2015; Duckett et al., 2016). On the other hand, we need to strengthen the active health management role of primary medical institutions for patients with chronic diseases; establish a community comprehensive medical team including doctors, pharmacists, nurses, and other professionals; and actively manage the diseases of patients in the local area to regain patients' confidence to primary medical institutions (Li et al., 2020; World Bank Group, 2021). In addition, some patients with chronic diseases do not realize the impact of national policies on the improvement of primary medical institutions; we need to strengthen the publicity of the improvement of primary medical institutions to patients, so that patients can understand and trust the medical service capability of new primary medical institutions and to have a usual primary care provider.

The Effect of Demographic and Clinical conditions on Polypharmacy Behaviors

With regard to the demographic and disease-related factors, patients with more diseases, severe disease, and disease history of more than 20 years are more likely to have polypharmacy behaviors. Patients aged 65–75 years, used to be brain workers, with disease history between 10 and 20 years, had adverse drug reactions, and insured by urban and rural residents' medical insurance were less likely to have polypharmacy behaviors.

The younger patients were associated with polypharmacy behaviors, which is consistent with existing studies (Dwyer et al., 2010; Olsson et al., 2010; Bronskill et al., 2012; Ruths et al., 2013; Nørgaard et al., 2017). The incidence of polypharmacy behaviors decreases with age, which may be related to the increased focus on discontinuing unnecessary medications in older adults with limited life expectancy (Holmes, 2009; Onder et al., 2012).

It is well known that patients with more diseases are more likely to have polypharmacy behaviors (Dwyer et al., 2010), but this study shows that the incidence of multiple drugs' exponential growth as the disease increased should be noted. For patients with chronic diseases, the marginal effect increased by 0.09 from having one disease to having two diseases, indicating a 9.0% increase in the incidence of polypharmacy behaviors. For patients with chronic diseases, the marginal effect increased by 0.40 from having one disease to have three or more diseases, indicating that when other variables were kept at the average level, changes in the number of cases from 1 to 3 or more resulted in a 40.0% increase in the incidence of polypharmacy behaviors.

Patients with a disease history between 11 and 20 years have a lower incidence of polypharmacy behaviors, while patients with a disease history of 21 years and above have a higher incidence of polypharmacy behaviors, which may be related to the health awareness and disease situation of patients with chronic diseases. Patients with a disease history of 11–20 years are aware of the physical damage caused by taking multiple drugs, so they will consciously reduce unnecessary drugs. But patients who had been ill for 21 years or more had to take multiple drugs for their poor health.

Brain workers were less likely to have polypharmacy behaviors, which may be related to the greater job pressure of physical workers (Tan et al., 2020). The incidence of polypharmacy behaviors was lower in patients with adverse drug reactions, which may be because patients with chronic disease are afraid of adverse drug reactions and become more careful in drug use, resulting in a lower incidence of polypharmacy behaviors.

The Influence of Medical Treatment and Health Behavior on Polypharmacy Behaviors

The incidence of polypharmacy behaviors is higher among patients who participated in urban employee medical insurance. Most of the patients who buy urban employee medical insurance are in economically developed areas; they have access to more sources of drugs, such as pharmacies, hospitals, and primary medical institutions. Therefore, polypharmacy behaviors are prone to occur. In addition, some patients who purchase urban employee medical insurance even have designated cooperative hospitals; it has been shown that patients who frequently visit hospitals have a higher incidence of polypharmacy behaviors than those who tend to visit primary medical institutions.

Patients who had frequent communication with their physicians had a higher incidence of polypharmacy behaviors; doctor–patient shared decision-making has been promoted in recent years, which can effectively improve patient compliance, patient satisfaction, and curative effect and make more beneficial choices for patients (Légaré et al., 2014; van Hoorn et al., 2016; Spatz et al., 2017). Doctor–patient shared decision can promote effective communication between doctors and patients to make medical decisions, rather than increasing the frequency of doctor–patient communication. The frequency of communication between doctors and patients indicates that patients may be treated in multiple departments or places, resulting in repeated prescriptions or prescription cascades that will increase the incidence of polypharmacy behaviors.

The incidence of polypharmacy behaviors is higher in patients with alcoholism. Previous studies have confirmed that moderate alcohol consumption has certain effects on control of chronic diseases (Ford et al., 2012; Loef and Walach, 2012; Zhu et al., 2019; Minzer et al., 2020), but alcoholism was associated with diseases such as cancer, hypertension, and liver disease, so patients who drink frequently were more likely to suffer from more diseases; polypharmacy behaviors were also more likely to happen. It was found that patients who have a meat-based diet or vegetarian-based diet are more prone to polypharmacy behaviors compared to patients who have a balanced diet. Patients with a meat-based diet are more prone to be diagnosed with hypertension, hyperlipidemia, diabetes, and other chronic diseases, so they are more prone to have polypharmacy behaviors happen, and the vegetarian-based patients may have lower body immunity and are prone to disease. In addition, some patients are recommended by doctors to use dietary therapy and other drug substitution therapy to treat chronic diseases, so patients with balanced meat and vegetable may use dietary therapy instead of drug therapy and take fewer drugs (Morgan et al., 2004; Hoel et al., 2021).

According to the findings in this study on the impact of patients' health behaviors and medical treatment behaviors on polypharmacy behaviors, corresponding intervention measures can be taken to prevent polypharmacy behaviors. For the patients who purchase urban employees' medical insurance, we should strengthen the publicity of rational drug use knowledge to avoid polypharmacy behaviors due to their exposure to multiple drug sources. Moreover, we should encourage effective communication between doctors and patients, instead of frequent communication. We should also encourage patients to use alternative therapies such as dietary therapy instead of drug therapy to reduce the possibility of polypharmacy behaviors, while encouraging patients to maintain a reasonable diet and moderate alcohol consumption is also very important to control polypharmacy behaviors.

Strengths and Limitations

Our study has several limitations. Various definitions of polypharmacy existed in the literature; we only considered the number of drugs used, namely ≥5 drugs as polypharmacy, so it is difficult to make a distinction between necessary prescribing and polypharmacy medication. Secondly, patients were recruited to search for samples, and patients who were unwilling to participate in the study were not investigated, which may lead to certain data bias. Third, since not all patients can remember all the medications, an underestimation of polypharmacy behaviors could not be completely ruled out.

Despite these limitations, this is a rare study in China that explores the impact of having a usual primary care provider on polypharmacy behaviors. Second, we used the propensity score weighting method to adjust for the observed difference in characteristics between those who have a usual primary care provider and those who do not. Third, the data we analyzed come from a large number of patients with hypertension or diabetes equally distributed throughout the 12 regions involved, which makes these evidences characteristic of and comparable to all patients with chronic diseases in Hubei province, China.

Conclusion

This study provides evidence that patients who had a usual primary care provider had a lower risk of polypharmacy. As we all know, in primary hospitals, the medical staffs have more time to communicate with patients and have a closer relationship with the patients; therefore, patient could have access convenient and economical services and obtain more guidance about drug use. Moreover, with the implementation of the hierarchical diagnosis and treatment and family physician system, the role and function of the primary care hospital in the system are providing integrated service for local residents. In consequence, the healthcare government should make efforts to construct community level medical institutions and improve the quality of health service to attract more patients, especially those with hypertension and diabetes.

Statements

Data availability statement

The data analyzed in this study are subject to the following licenses/restrictions: Because the data involve the patient's personal information, it cannot be provided. Requests to access these datasets should be directed to .

Ethics statement

The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients. This study was approved by the Medical Ethics Committee of Tongji Medical College of Huazhong University of Science and Technology, and the approval number is 2020 (S223).

Author contributions

All authors contributed to drafting and revising the manuscript. DF designed the study and reviewed the manuscript. JW completed the data analysis and drafted the initial manuscript. ZF, ZD, WL, CC, ZG, and AW critically reviewed the manuscript and proposed amendments.

Funding

This study was funded by the National Natural Science Youth Fund of China (Grant number: 71804052).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, orclaim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1

    BetteridgeT. M.FramptonC. M.JardineD. L. (2012). Polypharmacy--we Make it Worse! A Cross-Sectional Study from an Acute Admissions Unit. Intern. Med. J.42 (2), 208211. 10.1111/j.1445-5994.2011.02690.x

  • 2

    BronskillS. E.GillS. S.PatersonJ. M.BellC. M.AndersonG. M.RochonP. A. (2012). Exploring Variation in Rates of Polypharmacy across Long Term Care Homes. J. Am. Med. Dir. Assoc.13 (3), 309. 10.1016/j.jamda.2011.07.001

  • 3

    BrownS.CastelliM.HunterD. J.ErskineJ.VedstedP.FootC.et al (2014). How Might Healthcare Systems Influence Speed of Cancer Diagnosis: A Narrative Review. Soc. Sci. Med.116, 5663. 10.1016/j.socscimed.2014.06.030

  • 4

    BushardtR. L.MasseyE. B.SimpsonT. W.AriailJ. C.SimpsonK. N. (2008). Polypharmacy: Misleading, but Manageable. Dovepress3, 383389. 10.2147/CIA.S2468

  • 5

    ChenG.SangL.RongJ.YanH.LiuH.ChengJ.et al (2021). Current Status and Related Factors of Turnover Intention of Primary Medical Staff in Anhui Province, China: a Cross-Sectional Study. Hum. Resour. Health19 (1), 23. 10.1186/s12960-021-00563-6

  • 6

    CooneyD.PascuzziK. (2009). Polypharmacy in the Elderly: Focus on Drug Interactions and Adherence in Hypertension. Clin. Geriatr. Med.25 (2), 221233. 10.1016/j.cger.2009.01.005

  • 7

    DaleJ.PotterR.OwenK.ParsonsN.RealpeA.LeachJ. (2015). Retaining the General Practitioner Workforce in England: What Matters to GPs? A Cross-Sectional Study. BMC Fam. Pract.16 (1), 140. 10.1186/s12875-015-0363-1

  • 8

    DhalwaniN. N.FahamiR.SathanapallyH.SeiduS.DaviesM. J.KhuntiK. (2017). Association between Polypharmacy and Falls in Older Adults: A Longitudinal Study from England. BMJ Open7 (10), e016358. 10.1136/bmjopen-2017-016358

  • 9

    DuckettJ.HuntK.MunroN.SuttonM. (2016). Does Distrust in Providers Affect Health-Care Utilization in China?Health Policy Plan31 (8), 10011009. 10.1093/heapol/czw024

  • 10

    DwyerL. L.HanB.WoodwellD. A.RechtsteinerE. A. (2010). Polypharmacy in Nursing Home Residents in the United States: Results of the 2004 National Nursing Home Survey. Am. J. Geriatr. Pharmacother.8 (1), 6372. 10.1016/j.amjopharm.2010.01.001

  • 11

    FengD.SerranoR.YeT.TangS.DuanL.XuY.et al (2016). What Contributes to the Regularity of Patients with Hypertension or Diabetes Seeking Health Services? A Pilot Follow-Up, Observational Study in Two Sites in Hubei Province, China. Int. J. Env. Res. Pub. He.13 (12), 1268. 10.3390/ijerph13121268

  • 12

    FengD.ZhangD.LiB.ZhangY.SerranoR.ShiD.et al (2017). Does Having a Usual Primary Care Provider Reduce Patient Self-Referrals in Rural China's Rural Multi-Tiered Medical System? A Retrospective Study in Qianjiang District, China. BMC Health Serv. Res.17 (1), 778. 10.1186/s12913-017-2673-6

  • 13

    FialováD. (2005). Potentially Inappropriate Medication Use Among Elderly Home Care Patients in Europe. JAMA293 (11), 1348. 10.1001/jama.293.11.1348

  • 14

    FieldT. S.GurwitzJ. H.AvornJ.MccormickD.JainS.EcklerM.et al (2001). Risk Factors for Adverse Drug Events Among Nursing Home Residents. Arch. Intern. Med.161 (13), 1629. 10.1001/archinte.161.13.1629

  • 15

    FordE. S.BergmannM. M.BoeingH.LiC.CapewellS. (2012). Healthy Lifestyle Behaviors and All-Cause Mortality Among Adults in the United States. Prev. Med.55 (1), 2327. 10.1016/j.ypmed.2012.04.016

  • 16

    FultonM. M.AllenE. R. (2005). Polypharmacy in the Elderly: A Literature Review. J. Am. Acad. Nurse Pract.17 (4), 123132. 10.1111/j.1041-2972.2005.0020.x

  • 17

    GouldingM. R. (2004). Inappropriate Medication Prescribing for Elderly Ambulatory Care Patients. Arch. Intern. Med.164 (3), 305312. 10.1001/archinte.164.3.305

  • 18

    World Bank Group (2021). Deepening Health Reform in China : Building High-Quality and Value-Based Service Delivery. Available at: https://openknowledge.worldbank.org/handle/10986/24720 (accessed 11 28, 2021).

  • 19

    HanlonJ. T.PieperC. F.HajjarE. R.SloaneR. J.LindbladC. I.RubyC. M.et al (2006). Incidence and Predictors of All and Preventable Adverse Drug Reactions in Frail Elderly Persons after Hospital Stay. Journals Gerontol. Ser. A: Biol. Sci. Med. Sci.61 (5), 511515. 10.1093/gerona/61.5.511

  • 20

    HoelR. W.Giddings ConnollyR. M.TakahashiP. Y. (2021). Polypharmacy Management in Older Patients. Mayo Clin. Proc.96 (1), 242256. 10.1016/j.mayocp.2020.06.012

  • 21

    HolmesH. M. (2009). Rational Prescribing for Patients with a Reduced Life Expectancy. Clin. Pharmacol. Ther.85 (1), 103107. 10.1038/clpt.2008.211

  • 22

    JokanovicN.TanE. C.DooleyM. J.KirkpatrickC. M.BellJ. S. (2015). Prevalence and Factors Associated with Polypharmacy in Long-Term Care Facilities: A Systematic Review. J. Am. Med. Dir. Assoc.16 (6), 535. 10.1016/j.jamda.2015.03.003

  • 23

    KaufmanD. W.KellyJ. P.RosenbergL.AndersonT. E.MitchellA. A. (2002). Recent Patterns of Medication Use in the Ambulatory Adult Population of the United States: the Slone Survey. JAMA287 (3), 337344. 10.1001/jama.287.3.337

  • 24

    KrukM. E.PorignonD.RockersP. C.Van LerbergheW. (2010). The Contribution of Primary Care to Health and Health Systems in Low- and Middle-Income Countries: a Critical Review of Major Primary Care Initiatives. Soc. Sci. Med.70 (6), 904911. 10.1016/j.socscimed.2009.11.025

  • 25

    LauD. T.KasperJ. D.PotterD. E.LylesA.BennettR. G. (2005). Hospitalization and Death Associated with Potentially Inappropriate Medication Prescriptions Among Elderly Nursing home Residents. Arch. Intern. Med.165 (1), 6874. 10.1001/archinte.165.1.68

  • 26

    LeelakanokN.HolcombeA. L.LundB. C.GuX.SchweizerM. L. (2017). Association between Polypharmacy and Death: A Systematic Review and Meta-Analysis. J. Am. Pharm. Assoc. (2003)57 (6), 729738. 10.1016/j.japh.2017.06.002

  • 27

    LégaréF.StaceyD.TurcotteS.CossiM.KryworuchkoJ.GrahamI. D.et al (2014). Interventions for Improving the Adoption of Shared Decision Making by Healthcare Professionals. Cochrane Db. Syst. Rev.15 (9), CD006732. 10.1002/14651858.CD006732.pub3

  • 28

    LiX.KrumholzH. M.YipW.ChengK. K.De MaeseneerJ.MengQ.et al (2020). Quality of Primary Health Care in China: Challenges and Recommendations. Lancet395 (10239), 18021812. 10.1016/S0140-6736(20)30122-7

  • 29

    LiuX.XuL.WangS. (1996). Reforming China's 50,000 Township Hospitals-Eeffectiveness, Challenges and Opportunities. Health Policy38 (1), 1329. 10.1016/0168-8510(96)00834-2

  • 30

    LiuY.WangR.HuangR.CaoY.WangJ.FengD. (2021). Influencing Factors and Their Relationships of Risk Perception and Decision-Making Behaviour of Polypharmacy in Patients with Chronic Diseases: A Qualitative Descriptive Study. BMJ Open11 (4), e043557. 10.1136/bmjopen-2020-043557

  • 31

    LoefM.WalachH. (2012). The Combined Effects of Healthy Lifestyle Behaviors on All Cause Mortality: A Systematic Review and Meta-Analysis. Prev. Med.55 (3), 163170. 10.1016/j.ypmed.2012.06.017

  • 32

    MasnoonN.ShakibS.Kalisch-EllettL.CaugheyG. E. (2017). What Is Polypharmacy? A Systematic Review of Definitions. BMC Geriatr.17 (1), 230. 10.1186/s12877-017-0621-2

  • 33

    McphersonM. L.SmithS. W.PowersA.ZuckermanI. H. (2008). Association between Diabetes Patients' Knowledge about Medications and Their Blood Glucose Control. Res. Soc. Adm Pharm4 (1), 3745. 10.1016/j.sapharm.2007.01.002

  • 34

    MinzerS.EstruchR.CasasR. (2020). Wine Intake in the Framework of a Mediterranean Diet and Chronic Non-Communicable Diseases: A Short Literature Review of the Last 5 Years. Molecules25 (21), 5045. 10.3390/molecules25215045

  • 35

    MorganT. R.MandayamS.JamalM. M. (2004). Alcohol and Hepatocellular Carcinoma. Gastroenterology127 (5Suppl. 1), S87S96. 10.1053/j.gastro.2004.09.020

  • 36

    MortazaviS. S.ShatiM.KeshtkarA.MalakoutiS. K.BazarganM.AssariS. (2016). Defining Polypharmacy in the Elderly: A Systematic Review Protocol. BMJ Open6 (3), e010989. 10.1136/bmjopen-2015-010989

  • 37

    NørgaardA.Jensen-DahmC.GasseC.HansenE. S.WaldemarG.FischerC. (2017). Psychotropic Polypharmacy in Patients with Dementia: Prevalence and Predictors. J. Alzheimers Dis.56 (2), 707716. 10.3233/JAD-160828

  • 38

    O'ConnorM. N.GallagherP.O'MahonyD. (2012). Inappropriate Prescribing: Criteria, Detection and Prevention. Drugs Aging29 (6), 437452. 10.2165/11632610-000000000-00000

  • 39

    OkuyanB.SancarM.IzzettinF. V. (2013). Assessment of Medication Knowledge and Adherence Among Patients under Oral Chronic Medication Treatment in Community Pharmacy Settings. Pharmacoepidemiol. Drug Saf.22 (2), 209214. 10.1002/pds.3275

  • 40

    OlssonJ.BergmanA.CarlstenA.OkéT.BernstenC.SchmidtI. K.et al (2010). Quality of Drug Prescribing in Elderly People in Nursing Homes and Special Care Units for Dementia. Clin. Drug Invest.30 (5), 289300. 10.2165/11534320-000000000-00000

  • 41

    OnderG.LiperotiR.FialovaD.TopinkovaE.TosatoM.DaneseP.et al (2012). Polypharmacy in Nursing home in Europe: Results from the SHELTER Study. Journals Gerontology. Ser. A, Biol. Sci. Med. Sci.67 (6), 698704. 10.1093/gerona/glr233

  • 42

    PayneR. A.AveryA. J. (2011). Polypharmacy: One of the Greatest Prescribing Challenges in General Practice. Br. J. Gen. Pract.61 (583), 8384. 10.3399/bjgp11X556146

  • 43

    RuthsS.SorensenP. H.KirkevoldO.HuseboB. S.KrugerK.HalvorsenK. H.et al (2013). Trends in Psychotropic Drug Prescribing in Norwegian Nursing Homes from 1997 to 2009: A Comparison of Six Cohorts. Int. J. Geriatr. Psychiatry28 (8), 868876. 10.1002/gps.3902

  • 44

    SekhriN. K. (2000). Managed Care: The US Experience. Bull. World Health Organ.78 (6), 830844. 10.1590/S0042-96862000000600015

  • 45

    ShiL.MakinenM.LeeD. C.KidaneR.BlanchetN.LiangH.et al (2015). Integrated Care Delivery and Health Care Seeking by Chronically-Ill Patients - a Case-Control Study of Rural Henan Province, China. Int. J. Equity Health14, 98. 10.1186/s12939-015-0221-8

  • 46

    SpatzE. S.KrumholzH. M.MoultonB. W. (2017). Prime Time for Shared Decision Making. JAMA317 (13), 13091310. 10.1001/jama.2017.0616

  • 47

    StarfieldB.ShiL.MacinkoJ. (2005). Contribution of Primary Care to Health Systems and Health. Milbank Q.83 (3), 457502. 10.1111/j.1468-0009.2005.00409.x

  • 48

    StrandL. M.MorleyP. C.CipolleR. J.RamseyR.LamsamG. D. (1990). Drug-Related Problems: Their Structure and Function. DICP24 (11), 10931097. 10.1177/106002809002401114

  • 49

    TanE. C.PanK. Y.Magnusson HansonL. L.FastbomJ.WesterlundH.WangH. X. (2020). Psychosocial Job Strain and Polypharmacy: A National Cohort Study. Scand. J. Work Environ. Health46 (6), 589598. 10.5271/sjweh.3914

  • 50

    UK.GOV (2021). National Statistics Overview: Health Survey for England 2016 Findings and Trend Tables - GOV.UK. Available at: https://www.gov.uk/government/statistics/health-survey-for-england-2016-findings-and-trend-tables (accessed 11 26, 2021).

  • 51

    van HoornR.KievitW.BoothA.MozygembaK.LysdahlK. B.RefoloP.et al (2016). The Development of PubMed Search Strategies for Patient Preferences for Treatment Outcomes. BMC Med. Res. Methodol.16 (1), 88. 10.1186/s12874-016-0192-5

  • 52

    VerhaakP. F.van den Brink-MuinenA.BensingJ. M.GaskL. (2004). Demand and Supply for Psychological Help in General Practice in Different European Countries: Access to Primary Mental Health Care in Six European Countries. Eur. J. Public Health14 (2), 134140. 10.1093/eurpub/14.2.134

  • 53

    ViktilK. K.BlixH. S.EekA. K.DaviesM. N.MogerT. A.ReikvamA. (2012). How Are Drug Regimen Changes during Hospitalisation Handled after Discharge: A Cohort Study. BMJ Open2 (6), e001461. 10.1136/bmjopen-2012-001461

  • 54

    WastessonJ. W.MorinL.TanE. C. K.JohnellK. (2018). An Update on the Clinical Consequences of Polypharmacy in Older Adults: A Narrative Review. Expert Opin. Drug Saf.17 (12), 11851196. 10.1080/14740338.2018.1546841

  • 55

    XuX.MishraG. D.JonesM. (2017). Mapping the Global Research Landscape and Knowledge Gaps on Multimorbidity: A Bibliometric Study. J. Glob. Health7 (1), 010414. 10.7189/jogh.07.010414

  • 56

    YipW.HsiaoW. (2014). Harnessing the Privatisation of China's Fragmented Health-Care Delivery. Lancet384 (9945), 805818. 10.1016/S0140-6736(14)61120-X

  • 57

    ZhangX.XiongY.YeJ.DengZ.ZhangX. (2013). Analysis of Government Investment in Primary Healthcare Institutions to Promote Equity during the Three-Year Health Reform Program in China. BMC Health Serv. Res.13 (1), 114. 10.1186/1472-6963-13-114

  • 58

    ZhouZ.ZhaoY.ShenC.LaiS.NawazR.GaoJ. (2021). Evaluating the Effect of Hierarchical Medical System on Health Seeking Behavior: A Difference-In-Differences Analysis in China. Soc. Sci. Med.268, 113372. 10.1016/j.socscimed.2020.113372

  • 59

    ZhuN.YuC.GuoY.BianZ.HanY.YangL.et al (2019). Adherence to a Healthy Lifestyle and All-Cause and Cause-Specific Mortality in Chinese Adults: A 10-year Prospective Study of 0.5 Million People. Int. J. Behav. Nutr. Phys. Act16 (1), 98. 10.1186/s12966-019-0860-z

Summary

Keywords

polypharmacy, chronic disease, usual primary care providers, propensity score weight, service utilization

Citation

Wang J, Feng Z, Dong Z, Li W, Chen C, Gu Z, Wei A and Feng D (2022) Does Having a Usual Primary Care Provider Reduce Polypharmacy Behaviors of Patients With Chronic Disease? A Retrospective Study in Hubei Province, China. Front. Pharmacol. 12:802097. doi: 10.3389/fphar.2021.802097

Received

26 October 2021

Accepted

14 December 2021

Published

21 January 2022

Volume

12 - 2021

Edited by

Hui Shao, University of Florida, United States

Reviewed by

Zhong Li, Nanjing Medical University, China

Xia Li, China Pharmaceutical University, China

Updates

Copyright

*Correspondence: Da Feng,

This article was submitted to Pharmacoepidemiology, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics